Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
Tuberculosis (TB) remains a leading global cause of morbidity and mortality and an effective new vaccine is urgently needed. A major barrier to the rational development of novel TB vaccines is the lack of a validated immune correlate or biomarker of protection. Mycobacterial Growth Inhibition Assays...
Main Authors: | Rachel Tanner, Iman Satti, Stephanie A. Harris, Matthew K. O'Shea, Deniz Cizmeci, Daniel O'Connor, Agnieszka Chomka, Magali Matsumiya, Rachel Wittenberg, Angela M. Minassian, Joel Meyer, Helen A. Fletcher, Helen McShane |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.02983/full |
Similar Items
-
Whole Blood Mycobacterial Growth Assays for Assessing Human Tuberculosis Susceptibility: A Systematic Review and Meta-Analysis
by: Jeroen Bok, et al.
Published: (2021-05-01) -
Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection
by: Matthew K. O’Shea, et al.
Published: (2018-09-01) -
Age-Related Immunoreactivity Profiles to Diverse Mycobacterial Antigens in BCG-Vaccinated Chinese Population
by: Qing-yuan Yang, et al.
Published: (2021-01-01) -
BCG-induced disseminated mycobacterial infection of skin and bone in an otherwise immunocompetent child
by: Abhishek De, et al.
Published: (2017-01-01) -
Primary immunodeficiency leading to mycobacterial disease
by: Esther van de Vosse
Published: (2015-01-01)